Devyser and QIAGEN collaborate on pre-analytical workflow for fetal RHD screening
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
News | September 15, 2019
Cancer is overtaking heart disease as the leading cause of death, according to a study published recently in The Lancet medical journal.
While heart disease remains the overall leading cause globally, the study of nearly 156k participants, across 21 countries over 11 years, has identified a trend that as living conditions improve, cancer begins to overtake heart disease. In middle-income countries cancer approaches the same rate, while in high-income countries it represents more than double the deaths of heart disease. These two diseases alone account for nearly 80% of deaths in middle-aged adults.
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
Read More
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted...
Read More
“The first quarter of the year saw continued strong growth, record gross margin and the launching...
Read More
Devyser is today announcing that the company’s clinical testing laboratory in Roswell in Atlanta,...
Read More